Standard BioTools (LAB) Expected to Announce Earnings on Wednesday

Standard BioTools (NASDAQ:LAB) is expected to be releasing its earnings data after the market closes on Wednesday, February 26th. Analysts expect Standard BioTools to post earnings of ($0.07) per share and revenue of $43.03 million for the quarter. Persons interested in registering for the company’s earnings conference call can do so using this link.

Standard BioTools Price Performance

LAB opened at $1.33 on Tuesday. The firm has a fifty day moving average price of $1.67 and a 200 day moving average price of $1.81. Standard BioTools has a 1 year low of $1.17 and a 1 year high of $3.04. The stock has a market cap of $495.11 million, a P/E ratio of -1.87 and a beta of 1.57.

Wall Street Analyst Weigh In

Separately, TD Cowen cut their price target on shares of Standard BioTools from $2.75 to $2.50 and set a “buy” rating for the company in a report on Thursday, October 31st.

Standard BioTools Company Profile

Standard BioTools Inc, together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.